Stockreport

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics, Inc.  (PLRX) 
PDF Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral [Read more]